NAD+ and Mitochondria: How the Coenzyme Powers Your Cells

Edited by Samael A. Tejada, Founder & Editor-in-Chief

The short answer: NAD+ is the oxidized half of the cell's main electron-carrying pair, and your mitochondria cannot make energy without it. When you burn food for fuel, enzymes strip electrons from it and load them onto NAD+, turning it into NADH; NADH then delivers those electrons to the respiratory chain, which uses them to produce ATP. NAD+ levels decline with age in many tissues. Supplements of its precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — reliably raise NAD+ levels in human blood; that part is established. What trials have not yet shown is that raising NAD+ improves mitochondrial function, energy, or health outcomes in generally healthy people.

NAD+ is arguably the most marketed molecule in longevity. This guide explains what it does inside mitochondria, what actually raises it, and where the human evidence stops — claim by claim, with grades.

What does NAD+ actually do inside mitochondria?

Think of NAD+ as an empty delivery truck and NADH as the loaded one. In the mitochondria's fuel-processing cycle (the Krebs cycle) and in the step that feeds it, enzymes remove high-energy electrons from broken-down food molecules and load them onto NAD+, producing NADH. NADH drives to Complex I of the respiratory chain, unloads its electrons — which ultimately power ATP production — and returns as empty NAD+ to be loaded again. A single NAD+ molecule makes this round trip over and over, thousands of times.

NAD+ has a second job: it is consumed, not just cycled, by repair and signaling enzymes. Sirtuins — including SIRT3, which tunes mitochondrial enzymes — use NAD+ to regulate metabolism. PARP enzymes spend NAD+ repairing DNA damage. CD38, an enzyme that increases with age and inflammation, degrades it. That competition matters: the same pool that feeds energy production is also being spent on maintenance, and when spending rises or supply falls, the energy side can feel it. Established

Do NAD+ levels really fall with age?

In many tissues, yes. Measurements in human skin, blood, and brain, and in a wide range of animal tissues, show NAD+ falling with age — in some tissues by substantial fractions between youth and old age. Muscle data are more mixed. Proposed drivers are consistent with the biology above: CD38 activity rises with chronic low-grade inflammation, PARP enzymes consume more NAD+ as DNA damage accumulates, and NAMPT — the rate-limiting enzyme that recycles NAD+ building blocks — becomes less active. Established, with tissue-by-tissue variation

This decline is one reason mitochondrial function and aging are so often discussed together; our guide to mitochondrial function and aging covers the full picture.

Which supplements actually raise NAD+?

The best-supported route is not NAD+ itself but its precursors. NR and NMN feed the cell's salvage pathway — the recycling route that rebuilds NAD+ internally — and in randomized human trials both raise NAD+ concentrations in blood — by roughly half or more in several trials, depending on dose and tissue measured. Niacin (vitamin B3) also raises NAD+ and has for decades, though flushing and tolerability limit its use. Established — for raising measured levels

Swallowing NAD+ or NADH directly is a different story. Both are large, charged, fragile molecules; NADH oxidizes readily in acid, light, and air, and pharmacology reviews conclude that neither is absorbed intact in meaningful amounts — any effect likely comes from breakdown products. Whether they raise tissue NAD+ at all is unresolved. Contested We reviewed the trial record for NR specifically in our analysis of nicotinamide riboside human trials.

Does raising NAD+ improve mitochondrial function in people?

This is where the evidence thins out. Raising a blood level is not the same as improving mitochondrial function, and so far the functional readouts are modest and mixed. An influential early randomized trial of NR in healthy older adults (Martens et al., 2018) confirmed higher NAD+ levels but found no clear improvement in mitochondrial function, blood pressure, or physical performance. A 2021 trial of NMN in women with prediabetes found improved muscle insulin sensitivity — a real signal, in a specific group, on a metabolic endpoint rather than a direct mitochondrial one (Yoshino et al., Science). Other trials report small changes in walking distance, sleep scores, or muscle measures, inconsistently.

The fair summary: precursors do what they promise chemically (raise NAD+), and the case that this translates into better mitochondrial function or health in generally healthy people remains Preliminary — plausible, actively studied, and not yet demonstrated.

What about IV NAD+ drips?

Infusion clinics offer IV NAD+ as a faster, stronger version of the same idea, at high prices. The clinical evidence does not match the pitch. A 2026 systematic review of IV NAD+ and its precursors in wellness settings found only five small human studies, none adequately powered, all at high or some concern of bias, with safety data limited to small, short cohorts. NAD+ itself is also likely broken down into smaller intermediates before cells can use it, undercutting the 'direct flood' rationale. IV NAD+ is not FDA-approved for wellness or anti-aging. Our watchdog desk examined the evidence gap in our review of IV NAD+ claims. Absent — for outcome evidence

What is the honest bottom line on NAD+?

NAD+ is indispensable to mitochondria — that is textbook, not marketing. Its age-related decline is real, and NR and NMN demonstrably raise it. The open question is purely about payoff: whether pushing NAD+ above a healthy baseline improves mitochondrial function or health outcomes in people who are not deficient. Until larger trials with functional endpoints answer it, NAD+ boosters are best described as a well-grounded hypothesis with a price tag — not a proven mitochondrial therapy. For interventions with stronger human evidence today, see the top five actions for mitochondrial health.

Where the evidence stands

• Established: The NAD+/NADH redox pair is the core electron-handling system mitochondria use to convert food into ATP (standard biochemistry).
• Established: NR and NMN raise NAD+ levels in human blood in multiple randomized controlled trials.
• Established: NAD+ declines with age in many tissues, in human and animal data — though the size of the decline varies by tissue.
• Preliminary: Raising NAD+ improved muscle insulin sensitivity in one randomized trial in prediabetic women (NMN, Yoshino et al., Science, 2021); most functional endpoints in other trials have been neutral.
• Contested: Whether oral NAD+ or NADH supplements raise tissue NAD+ at all — pharmacology reviews find intact absorption unlikely and unproven.
• Absent: Evidence that IV NAD+ improves any health outcome in wellness users: a 2026 systematic review found only five small human studies and no adequately powered trial.